Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

Roche signs biologics partnership with Samsung

Roche signs biologics partnership with Samsung Roche's biologics portfolio includes the cancer drugs Kadcyla (trastuzumab emtansine) and Perjeta (pertuzumab), which launched this year and brought in 191m Swiss francs (about $214m) in the first half of

Roche invests $879m in its biologics future

Roche invests $879m in its biologics future If licensed obinutuzumab would join a portfolio of biologics that includes RoActemra (tocilizumab), Kadcyla (trastuzumab emtansine) and Perjeta (pertuzumab).

FDA gives green light to Roche for early Perjeta in breast cancer

FDA gives green light to Roche for early Perjeta in breast cancer A new approval pathway has made Perjeta available to people with HER2-positive early breast cancer several years earlier than previously possible.”. ... Roche also confirmed it was discussing the option of submitting Perjeta in the neoadjuvant setting

FDA panel backs Perjeta in early breast cancer

FDA panel backs Perjeta in early breast cancer If the FDA follows its committee's advice, Perjeta would become the cornerstone of the first regimen to get the go-ahead for neoadjuvant use in the US. ... Analysts have predicted that expansion of its use into the neoadjuvant setting could boost Perjeta

Pfizer faces NICE rejection for lung cancer drug

Pfizer faces NICE rejection for lung cancer drug Avastin (bevacizumab) and Perjeta (pertuzumab).

[ Previous 5 results ] 7 8 9 10 11 12 13 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics